Patents by Inventor Juergen Prestle

Juergen Prestle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11766443
    Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
  • Patent number: 11661458
    Abstract: Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Nina Zippel, Pankaj Gupta, Fei Han, Sarah Low, Juergen Prestle, Leo Thomas
  • Patent number: 11267880
    Abstract: The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Leo Thomas, Rachel Rebecca Barrett, Kristin Laura Bovat, Rajkumar Ganesan, Priyanka Gupta, Fei Han, Dongmei Liu, Juergen Prestle, Sanjaya Singh, Sathyadevi Venkataramani, Helen Haixia Wu, Nina Zippel
  • Patent number: 9346816
    Abstract: The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: May 24, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye
  • Publication number: 20120165304
    Abstract: The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Application
    Filed: November 26, 2009
    Publication date: June 28, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye